Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ji, Feng"'
Publikováno v:
Cancer Management and Research
Ji-Feng Feng,1,2 Jian-Ming Zhao,3 Sheng Chen,1 Qi-Xun Chen1,2 1Department of Thoracic Oncological Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sci
Publikováno v:
Cancer Management and Research. 11:7243-7251
Background We firstly identified a combination of lactate dehydrogenase (LDH) along with albumin (ALB), which was defined as LAR (LDH/ALB ratio). The purpose of our study here was initially to explore the prognostic role of LAR in patients with esoph
Publikováno v:
OncoTargets and Therapy. 12:5135-5142
Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alter
Autor:
Ye Chen, Nong Xu, Y.Q. Shu, Shujun Yang, F-H. Wang, Y. Liu, Yi Ba, Yi Jiang, R. Xu, Wei Li, X. C. Hu, Hao Wu, Q. Zhang, Xiaoyan Lin, H. Feng, Guanghai Dai, Qing Li, Liang Shen, S. Yao, X-L. Wei, Xianglin Yuan, Fulong Wang, J.W. Wang, Ji Feng Feng, J.H. Shi
Publikováno v:
Annals of Oncology
Cancer Communications
Cancer Communications
Background High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety and efficacy of tori
Autor:
Guangzhi Zhu, Guo-Dong Lu, Xiao-Wei Huang, Ji Feng, Wen-jing Su, Yong Wu, Jing Zhou, Chuangye Han, Shing Chung Hooi, Pei-Zhi Lu, Hui-Qi Dai, Xinping Ye, Tao Peng, Zhong-Jie Li, Pan-Hong Chen
Publikováno v:
Acta Pharmacol Sin
Sorafenib is the first-line treatment of advanced hepatocellular carcinoma (HCC). However, there is a lack of validated biomarkers to predict sorafenib sensitivity. In this study we investigated the role of ACSL4, a positive-activating enzyme of ferr
Publikováno v:
Oncotarget
// Qiang Zhao 1, 2 , Sheng Chen 1, 2 and Ji-Feng Feng 1, 2 1 Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, P.R.China 2 Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, P.R. China Correspondence t
Publikováno v:
Oncotarget
// Ji-Feng Feng 1, 2 , Sheng Chen 1, 2 and Xun Yang 1, 2 1 Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China 2 Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou 310022, China Correspondenc
Autor:
Yang Gao, Ji-feng Zhang, Qing-chang Li, Jia-jie Liu, Li-li Liu, Xue-feng Yang, Hua-mao Jiang, Hua-chuan Zheng
Publikováno v:
Oncotarget
// Yang Gao 1, * , Ji-feng Zhang 1, * , Qing-chang Li 2 , Jia-jie Liu 1 , Li-li Liu 1 , Xue-feng Yang 1 , Hua-mao Jiang 3 , Hua-chuan Zheng 1, 4 1 Cancer Center, Key Laboratory of Brain and Spinal Cord Injury of Liaoning Province, and Animal Center,
Autor:
Agnieszka Cseh, Ji Feng Feng, Dennis Chin-Lun Huang, Jiping Zhao, Eng Huat Tan, C.-T. Yang, H. Tu, W. Tang, C. Zhou, Konstantin Laktionov, Victor C. S. Lee, Antonio Passaro, A. Poltoratskiy, Dariusz M. Kowalski, F. De Marinis, B. Srinivasa, L. Clementi, Y-L. Wu, K. Park, Maya Gottfried
Publikováno v:
Annals of Oncology. 30:ix169-ix170
Background In the registrational trials, afatinib (afa) was active against NSCLC tumors harboring common and uncommon EGFR mutations, including G719X, L861Q and S768I,1 and is approved in this setting. Here, we assess 1st-line afa in pts with uncommo
Publikováno v:
Cancer biomarkers : section A of Disease markers. 23(3)
Objective Gastrulation brain homeobox 2 (GBX2), a gene involved in mid/hindbrain region, has been revealed as one of the oncogene associated with certain cancers, as an example being prostate cancer. However, despite years of worldwide research, the